ENANTA PHARMACEUTICA

ENTA
Delayed Quote. Delayed  - 01/22 04:00:00 pm
47.67USD +1.84%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: September 2020 2021
Net sales1 12299,2
EBITDA1 -18,4-107
Operating profit (EBIT)1 -41,6-91,3
Operating Margin -34,0%-92,1%
Pre-Tax Profit (EBT)1 -35,0-89,7
Net income1 -36,2-86,2
Net margin -29,5%-86,9%
EPS2 -1,81-4,14
Dividend per Share --
Last update 11/23/2020-
1 USD in Million
2 USD
Estimates
Finances - Leverage
Fiscal Period: September 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow1 5,64-80,7
ROE (Net Profit / Equities) -7,88%-27,4%
Shareholders' equity1 459314
ROA (Net Profit / Asset) -7,41%-25,7%
Assets1 488336
Book Value Per Share2 22,817,4
Cash Flow per Share --
Capex1 1,452,65
Capex / Sales 1,18%2,67%
Last update 11/23/202001/15/2021
1 USD in Million
2 USD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 960 M $ -
Valuation 2021e 2022e
P/E ratio (Price / EPS) -11,5x -8,34x
Capitalization / Revenue 9,68x 10,5x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,74x 4,43x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -92,1% -132%
Operating Leverage (Delta EBIT / Delta Sales) -6,28x -3,89x
Net Margin (Net Profit / Revenue) -86,9% -131%
ROA (Net Profit / Asset) -25,7% -49,2%
ROE (Net Profit / Equities) -27,4% -53,8%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   2,67% 3,07%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 3,38x 2,66x
Financial Leverage (Net Debt / EBITDA) - -
Price Earning Ratio
EPS & Dividend